Esketamine Nasal Spray for Rapid Reduction of Major Depressive Disorder Symptoms in Patients Who Have Active Suicidal Ideation With Intent: Double-Blind, Randomized Study (ASPIRE I)
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To compare esketamine to placebo, each in addition to standard-of-care treatment, for rapidly reducing major depressive disorder symptoms, including suicidal ideation. METHODS: This phase 3, double-blind, multicenter study (ASPIRE I), conducted between June 2017 and December 2018, enrolled 226 adults having major depressive disorder based on Diagnostic and Statistical Manual of Mental Disorders fifth edition (DSM-5) criteria, active suicidal ideation with intent, and need for psychiatric hospitalization. Patients were randomized 1:1 to esketamine 84 mg or placebo nasal spray twice-weekly for 4 weeks, each with comprehensive standard-of-care treatment (initial psychiatric hospitalization and newly initiated or optimized oral antidepressant[s] therapy). Change from baseline to 24 hours post-first dose in Montgomery-Asberg Depression Rating Scale (MADRS) total score (primary endpoint) was analyzed using analysis of covariance (ANCOVA), and change in Clinical Global Impression of Severity of Suicidality Revised version (CGI-SS-r; key secondary endpoint) score was analyzed using ANCOVA on ranks with treatment difference estimated using the Hodges-Lehmann estimate. RESULTS: Greater improvement in MADRS total score was observed with esketamine + standard-of-care versus placebo + standard-of-care at 24 hours (least-squares mean difference [SE]: -3.8 [1.39]; 95% CI, -6.56 to -1.09; 2-sided P = .006), as well as at earlier (4 hours) and later time points during 4-week double-blind treatment. The difference between groups in the severity of suicidality was not statistically significant (median of treatment difference [95% CI]: 0.0 [-1.00 to 0.00]; 2-sided P = .107). The most common adverse events among esketamine-treated patients were dizziness, dissociation, headache, nausea, and somnolence. CONCLUSIONS: These findings demonstrate rapid and robust efficacy of esketamine nasal spray in reducing depressive symptoms in severely ill patients with major depressive disorder who have active suicidal ideation with intent. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT03039192.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“With regard to esketamine in particular, clinical use was largely based on four positive Phase 3 efficacy studies [62][63][64][65] that informed the subsequent FDA approval of intranasal esketamine for TRD and suicidal ideation with intent, as described above.”
From Ketamine in neuropsychiatric disorders: an update (2024) · cites this paper as [63]
Experimental — accuracy not yet measuredIn the citing paper
“Most recently, Fu and colleagues demonstrated moderately significant AD effects with adjunct intranasal (IN) esketamine but failed to demonstrate an effect for suicidality, the trial’s other primary outcome.”
From Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression (2023) · cites this paper as [104]
In the citing paper
“In 2019, esketamine nasal spray (marketed as Spravato) was approved as an adjunctive AD treatment for TRD in the United States and the European Union, becoming the first novel-acting antidepressant approved in decades [104,105].”
From Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression (2023) · cites this paper as [104]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Suicide as an outcome for mental disorders: A meta-analysis
Harris, E. C., & Barraclough, B. (1997) · British Journal of Psychiatry · doi:10.1192/bjp.170.3.205 · Cited by 2,589
Epidemiology of Adult DSM-5 Major Depressive Disorder and Its Specifiers in the United States
Hasin, D. S., Sarvet, A. L., Meyers, J. L., Saha, T. D., Ruan, W. J., Stohl, M., & Grant, B. F. (2018) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.4602 · Cited by 1,737
Kessler, R. C. (2005) · JAMA · doi:10.1001/jama.293.20.2487 · Cited by 1,073
Wilkinson, S. T., Ballard, E. D., Bloch, M. H., Mathew, S. J., Murrough, J. W., Feder, A., Sos, P., Wang, G., Zarate, C. A., & Sanacora, G. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2017.17040472 · Cited by 696
Self-citationThe European Psychiatric Association (EPA) guidance on suicide treatment and prevention
Wasserman, D., Rihmer, Z., Rujescu, D., Sarchiapone, M., Sokolowski, M., Titelman, D., Zalsman, G., Zemishlany, Z., & Carli, V. (2012) · European Psychiatry · doi:10.1016/j.eurpsy.2011.06.003 · Cited by 390
Deisenhammer, E. A., Ing, C.-M., Strauss, R., Kemmler, G., Hinterhuber, H., & Weiss, E. M. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.07m03904 · Cited by 315
Holma, K. M., Melartin, T. K., Haukka, J., Holma, I. A. K., Sokero, T. P., & Isometsä, E. T. (2010) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2010.09050627 · Cited by 248
Deisenhammer, E., Ing, C.-M., Strauss, R., Kemmler, G., Hinterhuber, H., & Weiss, E. M. (2009) · PubMed · Cited by 237
Lifetime suicide risk in major depression: sex and age determinants
Blair-West, G. W., Cantor, C. H., Mellsop, G. W., & Eyeson-Annan, M. L. (1999) · Journal of Affective Disorders · doi:10.1016/s0165-0327(99)00004-x · Cited by 233
Suicide Attempts Among Patients Starting Depression Treatment With Medications or Psychotherapy
Simon, G. E., & Savarino, J. (2007) · American Journal of Psychiatry · doi:10.1176/ajp.2007.164.7.1029 · Cited by 168
Cited by
McIntyre, R. S., Rosenblat, J. D., Nemeroff, C. B., Sanacora, G., Murrough, J. W., Berk, M., Brietzke, E., Dodd, S., Gorwood, P., Ho, R., et al. (2021) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2020.20081251 · Cited by 731
“Notwithstanding the failure to detect a difference in suicidal ideation, the studiesprovided thebasis for theFDAapproval of esketamine for the treatment of major depressive disorder withsuicidal ideationorbehavior (77, 78).”
BackgroundSelf-citationOvercoming barriers to patient adherence: the case for developing innovative drug delivery systems
Baryakova, T. H., Pogostin, B. H., Langer, R., & McHugh, K. J. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00670-0 · Cited by 492
Ionescu, D. F., Fu, D.-J., Qiu, X., Lane, R., Lim, P., Kasper, S., Hough, D., Drevets, W. C., Manji, H., & Canuso, C. M. (2021) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaa068 · Cited by 418
Self-citationSuicide and Suicide Risk in Adolescents
Hua, L. L., Lee, J., Rahmandar, M. H., Sigel, E. J., COMMITTEE ON ADOLESCENCE, & COUNCIL ON INJURY, V. (2024) · Pediatrics · doi:10.1542/peds.2023-064800 · Cited by 205
Ketamine for the treatment of major depression: a systematic review and meta-analysis
Nikolin, S., Rodgers, A., Schwaab, A., Bahji, A., Zarate, C., Vazquez, G., & Loo, C. (2023) · eClinicalMedicine · doi:10.1016/j.eclinm.2023.102127 · Cited by 172
Aiding and Abetting Anhedonia: Impact of Inflammation on the Brain and Pharmacological Implications
Lucido, M. J., Bekhbat, M., Goldsmith, D. R., Treadway, M. T., Haroon, E., Felger, J. C., & Miller, A. H. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000043 · Cited by 137
Xiong, J., Lipsitz, O., Chen-Li, D., Rosenblat, J. D., Rodrigues, N. B., Carvalho, I., Lui, L. M. W., Gill, H., Narsi, F., Mansur, R. B., et al. (2021) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2020.12.038 · Cited by 124
“In the two trials testing IN esketamine, no statistically significant improvements in SI were reported in ketamine-treatment patients compared to the placebo at the 24-h time point (Canuso et al., 2018; Fu et al., 2020).”
BackgroundKetamine in neuropsychiatric disorders: an update
Johnston, J. N., Kadriu, B., Kraus, C., Henter, I. D., & Zarate, C. A. (2024) · Neuropsychopharmacology · doi:10.1038/s41386-023-01632-1 · Cited by 108
Vázquez, G. H., Bahji, A., Undurraga, J., Tondo, L., & Baldessarini, R. J. (2021) · Journal of Psychopharmacology · doi:10.1177/02698811211013579 · Cited by 95
Dean, R. L., Hurducas, C., Hawton, K., Spyridi, S., Cowen, P. J., Hollingsworth, S., Marquardt, T., Barnes, A., Smith, R., McShane, R., et al. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011612.pub3 · Cited by 95
Prevention of suicidal behavior in bipolar disorder
Tondo, L., Vázquez, G. H., & Baldessarini, R. J. (2020) · Bipolar Disorders · doi:10.1111/bdi.13017 · Cited by 104
“Juveniles with BD 6550 [6040-7100] 124 [57-236] 52.”
Canuso, C. M., Ionescu, D. F., Li, X., Qiu, X., Lane, R., Turkoz, I., Nash, A. I., Lopena, T. J., & Fu, D.-J. (2021) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001465 · Cited by 88
“This proof-of-concept study gave rise to 2 identically designed, phase 3 global studies of adults with MDD who had active suicidal ideation with intent (ASPIRE I and ASPIRE II).(23,24) In the United States, these studies formed the basis of the approval of esketamine for the treatment of depressive symptoms in adults…”
BackgroundMethodResultInfluentialSelf-citationEsketamine Treatment for Depression in Adults: A PRISMA Systematic Review and Meta-Analysis
Fountoulakis, K. N., Saitis, A., & Schatzberg, A. F. (2025) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20240515 · Cited by 90
Kasper, S., Cubała, W. J., Fagiolini, A., Ramos-Quiroga, J. A., Souery, D., & Young, A. H. (2021) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2020.1836399 · Cited by 85
Esketamine for Treatment-Resistant Depression: A Review of Clinical Evidence (Review)
Vasiliu, O. (2023) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2023.11810 · Cited by 82
“MADRS scores indicated a significantly greater improvement in patients treated with esketamine 24 h after the first dose (31).”
InfluentialBahji, A., Zarate, C. A., & Vazquez, G. H. (2022) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2022.2047928 · Cited by 73
Novel Pharmacological Approaches to the Treatment of Depression
Elias, E., Zhang, A. Y., & Manners, M. T. (2022) · Life · doi:10.3390/life12020196 · Cited by 89
“Additionally, this enantiomer is used for patients with severe illness or active suicidal thoughts [82].”
BackgroundSiegel, A. N., Di Vincenzo, J. D., Brietzke, E., Gill, H., Rodrigues, N. B., Lui, L. M. W., Teopiz, K. M., Ng, J., Ho, R., McIntyre, R. S., et al. (2021) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2021.03.009 · Cited by 70
Glutamatergic Modulators for Major Depression from Theory to Clinical Use
McIntyre, R. S., & Jain, R. (2024) · CNS Drugs · doi:10.1007/s40263-024-01114-y · Cited by 69
Chen, G., Chen, L., Zhang, Y., Li, X., Lane, R., Lim, P., Daly, E. J., Furey, M. L., Fedgchin, M., Popova, V., et al. (2022) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyab084 · Cited by 71
Self-citationTakahashi, N., Yamada, A., Shiraishi, A., Shimizu, H., Goto, R., & Tominaga, Y. (2021) · BMC Psychiatry · doi:10.1186/s12888-021-03538-y · Cited by 57
Ketamine and esketamine in suicidal thoughts and behaviors: a systematic review
Jollant, F., Colle, R., Nguyen, T. M. L., Corruble, E., Gardier, A. M., Walter, M., Abbar, M., & Wagner, G. (2023) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253231151327 · Cited by 56
The rapid anti-suicidal ideation effect of ketamine: A systematic review
Hochschild, A., Grunebaum, M. F., & Mann, J. J. (2021) · Preventive Medicine · doi:10.1016/j.ypmed.2021.106524 · Cited by 55
McQuaid, J. R., Buelt, A., Capaldi, V., Fuller, M., Issa, F., Lang, A. E., Hoge, C., Oslin, D. W., Sall, J., Wiechers, I. R., et al. (2022) · Annals of Internal Medicine · doi:10.7326/m22-1603 · Cited by 59
“However, the effectiveness of esketamine in preventing suicide or reducing suicidal ideation or behavior has not been established (35, 36).”
BackgroundPrescriber's Guide: Stahl's Essential Psychopharmacology
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275 · Cited by 87
Wang, S.-M., Kim, N.-Y., Na, H.-R., Lim, H. K., Woo, Y. S., Pae, C.-U., & Bahk, W.-M. (2021) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2021.19.2.341 · Cited by 52
“Four [15,16,20,21] studies used flexible doses while other four [17,19,29,30] used fixed doses of intranasal esketamine.”
BackgroundInfluentialFeeney, A., & Papakostas, G. I. (2023) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2023.02.003 · Cited by 64
Su, T., Li, C., Lin, W., Wu, H.-J., Tsai, S., Bai, Y., Mao, W., Tu, P., Chen, L., Li, W., et al. (2023) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyad014 · Cited by 66
Reporting of harms in clinical trials of esketamine in depression: a systematic review
de Laportalière, T. T., Jullien, A., Yrondi, A., Cestac, P., & Montastruc, F. (2023) · Psychological Medicine · doi:10.1017/s0033291723001058 · Cited by 58
“1) (Canuso et al., 2018; Daly et al., 2018, 2019; Fedgchin et al., 2019; Fu et al., 2020; Ionescu et al., 2021; Table 1.”
Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression
Vecera, C. M., C. Courtes, A., Jones, G., Soares, J. C., & Machado-Vieira, R. (2023) · Pharmaceuticals · doi:10.3390/ph16111572 · Cited by 48
“In fact, with seven suicide attempts and one completion by a patient who had received esketamine just three days prior, Fu and colleagues’ findings may draw a troubling parallel to SSRI black box warnings [104].”
BackgroundTherapeutic potential of ketamine for alcohol use disorder
Worrell, S. D., & Gould, T. J. (2021) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2021.05.006 · Cited by 52
Safety and effectiveness of NMDA receptor antagonists for depression: A multidisciplinary review
Moore, T. J., Alami, A., Alexander, G. C., & Mattison, D. R. (2022) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2707 · Cited by 50
Psiuk, D., Nowak, E., Dycha, N., Łopuszańska, U., Kurzepa, J., & Samardakiewicz, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911450 · Cited by 54
“The improvement in severity of suicidality was also observed on the 25th day of the treatment [37,40].”
BackgroundMethodInfluentialInpatient suicide in psychiatric settings: Evaluation of current prevention measures
Chammas, F., Januel, D., & Bouaziz, N. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.997974 · Cited by 38
Chen, X., Hou, X., Bai, D., Lane, R., Zhang, C., Canuso, C., Wang, G., & Fu, D.-J. (2023) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s391096 · Cited by 35
Self-citationFeeney, A., Hock, R. S., Freeman, M. P., Flynn, M., Hoeppner, B. B., Iosifescu, D. V., Trivedi, M. H., Sanacora, G., Mathew, S. J., DeBattista, C., et al. (2021) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2021.04.024 · Cited by 42
Self-citationDomany, Y., & McCullumsmith, C. B. (2021) · Archives of Suicide Research · doi:10.1080/13811118.2021.1878078 · Cited by 35
Pharmacologic approaches to suicide prevention
Zisook, S., Domingues, I., & Compton, J. (2023) · Focus · doi:10.1176/appi.focus.20220076 · Cited by 30
Chen, C., Zhou, N., Hu, N., Feng, J., & Wang, X. (2023) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s401032 · Cited by 39
Drug Repurposing for the Management of Depression: Where Do We Stand Currently?
Sadeghi, H. M., Adeli, I., Mousavi, T., Daniali, M., Nikfar, S., & Abdollahi, M. R. (2021) · Life · doi:10.3390/life11080774 · Cited by 31
“Esketamine Phase III/2017 [117,118] 84 mg intranasal, twice a week (on days 1,4,8,11,15,18,22 and 25) along with the standard of care antidepressant treatment initiated on day 1 (4 weeks) 225/139/86 MDD and have suicidal ideation with intent but without psychotic features P = 112 Tx = 113 R, PG, DB, PC, multi-center ↓…”
MethodCapuzzi, E., Caldiroli, A., Capellazzi, M., Tagliabue, I., Marcatili, M., Colmegna, F., Clerici, M., Buoli, M., & Dakanalis, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179338 · Cited by 41
“Some studies may be affected by moderate [28] to high risk of bias [26,30] as well as presenting some concerns in term of risk of bias [31,32].”
BackgroundMethodInfluentialAlphs, L. D., Fu, D., Williamson, D., Turkoz, I., Jamieson, C., Revicki, D. A., & Canuso, C. M. (2020) · Psychiatry Research · doi:10.1016/j.psychres.2020.113495 · Cited by 28
“…Suicide Ideation and Behavior Assessment Tool; S-STS CMCM, Sheehan Suicidality Tracking Scale Clinically Meaningful Change Measure time intervals (i.e., within hours) and documents clinician assessment of the severity of suicidality and suicide risk and plans for its management (Fu et al., 2020).”
MethodSelf-citationXin, N., Yan, W., & Jin, S. (2022) · BioMed Research International · doi:10.1155/2022/5095282 · Cited by 29
“In addition, its sympathetic properties counteract the hemodynamic depressant effects of propofol, thereby reducing the risk of cardiovascular and respiratory depression during sedation (23).”
BackgroundRetractedBoudieu, L., Mennetrier, M., Llorca, P., & Samalin, L. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15122773 · Cited by 32
“…a significant decrease in depressive symptoms in comparison with placebo groups in several short-term randomized placebo-controlled studies [30,31,33,35,38,39] and has shown superior remission rates at week 8 in comparison to extended-release quetiapine in a randomized active-controlled study of…”
BackgroundMethodResultInfluentialEffects of somatic treatments on suicidal ideation and completed suicides
Hawkins, E. M., Coryell, W. H., Leung, S., Parikh, S. V., Weston, C. L., Nestadt, P. S., Nürnberger, J. I., Kaplin, A. I., Kumar, A., Farooqui, A. A., et al. (2021) · Brain and Behavior · doi:10.1002/brb3.2381 · Cited by 31
“Each group received treatment twice weekly for a span of 4 weeks while receiving comprehensive standard treatment of care, including a new or optimized antidepressant (Fu et al., 2020).”
BackgroundMethodInfluentialKato, M., Nakagome, K., Baba, T., Sonoyama, T., Okutsu, D., Yamanaka, H., Shimizu, R., Motomiya, T., & Inoue, T. (2023) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.13569 · Cited by 32
“006 for both, respectively) and thereafter over the 4-week double-blind treatment.(36,37) Although a direct comparison cannot be made, the improvement in the zuranolone 20- and 30-mg groups vs the placebo group was similar to that achieved with rapid-acting agents that exert their effects via modulation of glutamate/G…”
ResultKetamine vs midazolam: Mood improvement reduces suicidal ideation in depression
Hochschild, A., Keilp, J. G., Madden, S. P., Burke, A. K., Mann, J. J., & Grunebaum, M. F. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2021.12.055 · Cited by 25
Lengvenytė, A., Olié, É., Strumila, R., Navickas, A., González-Pinto, A. M., & Courtet, P. (2021) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2021.1907712 · Cited by 26
“Only six studies justified their sample size by performing power calculations to detect meaningful differences in SI (Yovell et al. 2016; Grunebaum et al. 2018; Diamond et al. 2019; McCall et al. 2019; Fu et al. 2020; Ionescu et al. 2020), and one study performed power calculations to detect differences in SA within s…”
BackgroundInfluentialZhou, Y., Wang, C., Lan, X., Zheng, W., Li, H., Chao, Z., Wu, K., McIntyre, R. S., & Ning, Y. (2021) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2021.10.037 · Cited by 25
Sex differences in ketamine's therapeutic effects for mood disorders: A systematic review
Benitah, K. C., Siegel, A. N., Lipsitz, O., Rodrigues, N. B., Meshkat, S., Lee, Y. L., Mansur, R. B., Nasri, F., Lui, L. M. W., McIntyre, R. S., et al. (2022) · Psychiatry Research · doi:10.1016/j.psychres.2022.114579 · Cited by 25
Halaris, A. E., & Cook, J. T. (2023) · Advances in experimental medicine and biology · doi:10.1007/978-981-19-7376-5_21 · Cited by 32
Nikayin, S., & Sanacora, G. (2021) · CNS Drugs · doi:10.1007/s40263-021-00851-8 · Cited by 26
Self-citationEsketamine versus placebo on time to remission in major depressive disorder with acute suicidality
Fu, D., Zhang, Q., Shi, L., Borentain, S., Guo, S., Mathews, M., Anjo, J., Nash, A. I., O’Hara, M., & Canuso, C. M. (2023) · BMC Psychiatry · doi:10.1186/s12888-023-05017-y · Cited by 24
“The full list can be found in Additional File 1 as well as in the supplementary materials of the primary publications [16, 17].”
BackgroundMethodInfluentialSelf-citationKetamine and esketamine for crisis management in patients with depression: Why, whom, and how?
Lengvenytė, A., Strumila, R., Olié, É., & Courtet, P. (2022) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2022.02.004 · Cited by 21
Gonda, X., Döme, P., Serafini, G., & Pompili, M. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108390 · Cited by 22
Tsang, V. W. L., Tao, B. K.-L., Dames, S., Walsh, Z., & Kryskow, P. (2023) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253231171512 · Cited by 21
Surjan, J., Grossi, J. D., Del Porto, J. A., Delfino, R. S., de Oliveira Cerqueira, R., Lucchese, A. C., Magalhães, E., Del Sant, L. C., Tuena, M. A., Nakahira, C., et al. (2022) · Clinical Drug Investigation · doi:10.1007/s40261-022-01193-z · Cited by 19
Kosik‐Gonzalez, C., Fu, D., Chen, L. N., Lane, R., Bloch, M. H., DelBello, M. P., Moreno, C., Drevets, W. C., & Canuso, C. M. (2025) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1016/j.jaac.2025.02.015 · Cited by 26
Self-citationMatsingos, A., Wilhelm, M., Noor, L., Yildiz, C., Rief, W., Hofmann, S. G., Falkenberg, I., & Kircher, T. T. J. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1346697 · Cited by 27
Lucido, M. J., & Dunlop, B. W. (2025) · Brain Sciences · doi:10.3390/brainsci15020161 · Cited by 23
Translating Interventional Neuroscience to Suicide: It’s About Time
Barredo, J., Bozzay, M. L., Primack, J. M., Schatten, H. T., Armey, M. F., Carpenter, L. L., & Philip, N. S. (2021) · Biological Psychiatry · doi:10.1016/j.biopsych.2021.01.013 · Cited by 23
“, (119,121)], but aggregated evidence was sufficiently compelling for the Food and Drug Administration’s approval of esketamine for MDD with acute STBs.”
Liu, P., Zhang, S., Liang, Y., Gao, Z., Gao, W., & Dong, B. (2022) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s388764 · Cited by 21
Esketamine in depression: putative biomarkers from clinical research
Johnston, J. N., Zarate, C. A., & Kvarta, M. D. (2024) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-024-01865-1 · Cited by 23
“Monitoring is recommended for at least two hours after administration, which may require reporting of vital signs and return to baseline functioning to a centralized monitoring system.”
Hecking, J., Davoudian, P. A., & Wilkinson, S. T. (2021) · Chronic Stress · doi:10.1177/24705470211020446 · Cited by 20
“30, respectively).(17,18,40) AVP-786 AVP is an oral formulation that combined dextromethorphan and quinidine.”
BackgroundPan, Y., Gorenflo, M. P., Davis, P. B., Kaelber, D. C., Luca, S. M. D., & Xu, R. (2024) · Translational Psychiatry · doi:10.1038/s41398-024-03033-4 · Cited by 25
“Findings from this study provide data to balance the bene fi ts of ketamine with its reported adverse effects, such as dissociation, psychosis, hypertension, tachycardia, tolerance, and addiction [41, 54, 64].”
MethodOraee, S., Alinejadfard, M., Golsorkh, H., Sadeghian, M., Fanaei, M., Centis, R., D’Ambrosio, L., Sotgiu, G., Goudarzi, H., Migliori, G. B., et al. (2024) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2024.11.010 · Cited by 22
“Following the screening, 9 articles were identified as meeting the specified inclusion criteria (Canuso, 2019; Chen et al., 2023; Daly et al., 2018; Fedgchin et al., 2019; Fu et al., 2020; Ionescu et al.,”
Diekamp, B., Borentain, S., Fu, D., Murray, R., Heerlein, K., Zhang, Q., Schüle, C., & Mathews, M. (2021) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s314874 · Cited by 18
Self-citationCraving and addictive potential of esketamine as side effects?
Orsolini, L., Salvi, V., & Volpe, U. (2022) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2022.2071422 · Cited by 18
Blinding Integrity in Psychedelic Randomized Clinical Trials: A Systematic Review
Orsini, D. K., Wong, S., Luch, S. D. D., Chan, B., Vasudeva, S., Lovell, G. F. M., Le, G. H., Jones, B. D. M., Chisamore, N., Mollica, A., et al. (2026) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2026.0255 · Cited by 22
Wilkowska, A., & Cubała, W. J. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1322752 · Cited by 20
Kumari, S., Chaudhry, H. A., Sagot, A. J., Doumas, S. J., Abdullah, H. M., Alcera, E. C., Solhkhah, R., & Afzal, S. (2024) · Cureus · doi:10.7759/cureus.53987 · Cited by 28
“Moreover, researchers employed a key secondary endpoint by measuring the Clinical Global Impression of Severity of Suicidality-revised (CGISS-r) score, which saw rapid reductions in both ASPIRE I and II [17,18].”
BackgroundMethodInfluentialZhou, Y., Wang, C., Lan, X., Li, W., Chao, Z., Wu, K., McIntyre, R. S., & Ning, Y. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.779326 · Cited by 21
Esketamine: A Drug to Treat Resistant Depression That Brings More Questions Than Answers
Mischel, N., & Balon, R. (2021) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001395 · Cited by 20
Clinical Effects of Psychedelic Substances Reported to United States Poison Centers: 2012 to 2022
Simon, M. W., Olsen, H. A., Hoyte, C. O., Black, J. C., Reynolds, K. M., Dart, R. C., & Monte, A. A. (2024) · Annals of Emergency Medicine · doi:10.1016/j.annemergmed.2024.06.025 · Cited by 17
Chen, B. K., Pen, G. L., Eckmier, A., Rubinstenn, G., Jay, T. M., & Denny, C. A. (2021) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyab007 · Cited by 14
“…rapid efficacy for reducing symptoms of depression, including suicidality (Daly et al., 2018, 2019; Fedgchin et al., 2019; Popova et al., 2019; Fu et al., 2020; Ionescu et al., 2020; Nijs et al., 2020; Perez-Ruixo et al., 2020; Saad et al., 2020; Wajs et al., 2020; ClinicalTrials.gov,…”
Singh, B., Voort, J. L. V., Pazdernik, V., Frye, M. A., & Kung, S. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.01.262 · Cited by 23
Palhano-Fontes, F., Cavalcanti-Ribeiro, P., Gonçalves, K. T. D. C., de Almeida, V. R. N., Barbosa, D. C., Ferreira, M. A. D. A., Bolcont, R., Souza, L. C. A. M. D., dos Santos, N. C., Lopes, E. I. T. C., et al. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.09.141 · Cited by 14
Jamieson, C., Canuso, C. M., Ionescu, D. F., Lane, R., Qiu, X., Rozjabek, H., Molero, P., & Fu, D. (2023) · Quality of Life Research · doi:10.1007/s11136-023-03451-9 · Cited by 18
“In both studies, esketamine nasal spray plus SOC was associated with a rapid reduction in depressive symptoms of MDD in patients with active suicidal ideation with intent at 24 h after the first dose compared with a matched placebo nasal spray plus SOC, as assessed by clinician-rated outcome measures [11, 12].”
BackgroundMethodResultInfluentialSelf-citationPsychedelic Therapy: A Primer for Primary Care Clinicians—Ketamine
Evans, V. D., Arenas, A., Shinozuka, K., Tabaac, B. J., Beutler, B. D., Cherian, K. N., Fasano, C., & Muir, O. S. (2024) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001721 · Cited by 19
“149,150 The limited availability of evidence-based pharmacological treatments for SI in individuals with MDD and bipolar disorder underscores the urgent need for innovative interventions.”
BackgroundLiu, X., Wei, Z., Li, L., Li, J., Deng, Y., Liu, Y., Li, H., Peng, D., Wan, X., & Wu, G. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.12.002 · Cited by 16
(Es)Ketamine for Suicidal Ideation and Behavior: Clinical Efficacy
Alario, A. A., & Niciu, M. J. (2022) · Chronic Stress · doi:10.1177/24705470221128017 · Cited by 18
Pompili, M., Sarli, G., Erbuto, D., Manfredi, G., & Comparelli, A. (2022) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000455 · Cited by 18
Guo, H., Tang, L., He, M., Tang, W., Liu, J., Wu, S., Yuan, S., Wang, J., & Tang, X. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1681060 · Cited by 16
Zhdanava, M., Teeple, A., Pilon, D., Shah, A., Caron‐Lapointe, G., & Joshi, K. (2023) · Journal of Medical Economics · doi:10.1080/13696998.2023.2208993 · Cited by 14
“In this study patient ’ s mean age and sex ratio were comparable to those in the esketamine MDSI trials 18,30,31 ; a numerical decrease was observed in inpatient and emergency department visits and total healthcare costs 6 months following esketamine initiation, signaling a potential reduction in…”
ResultLopes, E. I. T. C., Cavalcanti-Ribeiro, P., Palhano-Fontes, F., Gonçalves, K. T. D. C., Nunes, E. A., Lima, N. B. D. M., dos Santos, N. C., de Brito, A. J. C., de Araújo, D. B., & Coelho, N. L. G. (2024) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2024.06.020 · Cited by 12
Pardossi, S., Fagiolini, A. M., Scheggi, S., & Cuomo, A. (2024) · Children · doi:10.3390/children11070801 · Cited by 23
“Several studies have demonstrated esketamine efficacy and safety in adults, even in the long term [40–45].”
BackgroundIs there a risk of esketamine misuse in clinical practice?
Roncero, C., Torres, M. M., Szerman, N., Torrens, M., Vega, P., Andrés-Olivera, P., & Alvarez, E. (2025) · Therapeutic Advances in Drug Safety · doi:10.1177/20420986241310685 · Cited by 18
Pharmacological Monotherapy for Depressive Disorders: Current and Future—A Narrative Review
Gao, K., Oruc, E. B., & Koparal, B. (2025) · Medicina · doi:10.3390/medicina61040558 · Cited by 14
“The approval for adults with MDD and acute SI and behavior was mainly based on two phase III studies [55,56].”
Intranasal esketamine use in bipolar disorder: A case report
Skriptshak, C., & Reich, A. (2021) · Mental Health Clinician · doi:10.9740/mhc.2021.07.259 · Cited by 12
Yao, Z., & McCall, W. V. (2023) · Pharmaceutical Medicine · doi:10.1007/s40290-023-00467-x · Cited by 16
“Two multicenter trials of esketamine in hospitalized patients with active suicidal intent compared with placebo (both groups received standard of care antidepressant with or without augmentation agent at investigators’ discretion) showed that esketamine improved Montgomery Åsberg Depression Rating Scale (MADRS) scores…”
BackgroundRyan, K., & Hosanagar, A. (2023) · Current Psychiatry Reports · doi:10.1007/s11920-023-01432-w · Cited by 11
Hovda, N., Gerrish, W. G., Frizzell, W., & Shackelford, R. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.10.120 · Cited by 15
Esketamine–A quick-acting novel antidepressant without the disadvantages of ketamine
Shoib, S., Kotra, M., Javed, S., Nguyen, V.-S., & Malathesh, B. C. (2022) · Hormone Molecular Biology and Clinical Investigation · doi:10.1515/hmbci-2021-0099 · Cited by 13
Floriano, I., Silvinato, A., & Bernardo, W. M. (2023) · Revista da Associação Médica Brasileira · doi:10.1590/1806-9282.2023d694 · Cited by 12
Anti-Suicidal Effects of Lithium, Ketamine, and Clozapine—A 10-Year Systematic Review
Waszak, P. M., Opalko, J., Olszańska, N., & Zagożdżon, P. (2025) · Pharmaceuticals · doi:10.3390/ph18050742 · Cited by 15
“Both Fu et al. and Ionescu et al. found no significant difference in suicidal ideation 24 h after first dosage [49,56].”
Kitay, B. M., Murphy, E., Macaluso, M., Corlett, P. R., Hershenberg, R., Joormann, J., Martinez‐Kaigi, V., Nikayin, S., Rhee, T. G., Sanacora, G., et al. (2023) · Psychiatry Research · doi:10.1016/j.psychres.2023.115585 · Cited by 13
Self-citationWhat clinicians need to know about intranasal esketamine for treatment-resistant depression?
Hope, J., Copolov, D., Tiller, J. W. G., Galbally, M., Hopwood, M., Newton, R., & Keks, N. A. (2023) · Australasian Psychiatry · doi:10.1177/10398562231211171 · Cited by 12
Alves-Pereira, R., Fontes, M., Cordeiro, V., Bandeira, I. D., Faria-Guimarães, D., Silva, S. S., Mello, R. P., Leal, G. C.-G., Sampaio, A. S., & Quarantini, L. C. (2024) · Clinical Neuropharmacology · doi:10.1097/wnf.0000000000000578 · Cited by 9
Chepke, C., Shelton, R. C., Sanacora, G., Doherty, T., Tsytsik, P., & Parker, N. (2024) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyae058 · Cited by 12
“…clinically relevant; therefore, they were not reported as adverse events (AEs) by the investigators in the majority of cases (Daly et al., 2019; Fedgchin et al., 2019; Popova et al., 2019; Fu et al., 2020; Ionescu et al., 2020; Ochs-Ross et al., 2020; Wajs et al., 2020; Reif et al., 2023).”
Self-citationEsketamine Nasal Spray in Major Depressive Disorder: A Meta‐Analysis of Randomized Controlled Trials
Wang, Z., Jiang, L., Ma, W., Li, X., Gao, Q., Lian, S., & Yu, W. (2025) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3555 · Cited by 15
“15,16 Furthermore, there exists inconsistency across the study outcomes from these existing RCTs. 13,14,17 Although an existing meta-analysis summarized current clinical evidence and indicated a favorable effect of intranasal esketamine administration in MDD, 18 it did not provide detailed…”
Self-citation
Metadata
- Authors
- Fu, D.-J., Ionescu, D. F., Li, X., Lane, R., Lim, P., Sanacora, G., Hough, D., Manji, H., Drevets, W. C., & Canuso, C. M.
- Affiliations
- Janssen Research & Development (United States) (US)
- Yale University (US)
- Corresponding author
- Fu, Dong-Jing
- ORCID
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2020-05-12
- Volume
- 81
- Issue
- 3
- ISSN
- 0160-6689 (ISSN-L)
- 1555-2101
- OpenAlex
- W3025905746
- Cited by
- 376
- References
- 13
- Citations by year
- 2026: 30 · 2025: 34 · 2024: 32 · 2023: 50 · 2022: 34 · 2021: 30 · 2020: 166
- FWCI
- 41.70
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- esketamine, nasal spray, major depressive disorder, suicidal ideation, rapid-acting antidepressants, psychiatric hospitalization, antidepressant-resistant depression, depressive symptom reduction, adverse events
- MeSH terms
- Administration, Intranasal, Adolescent, Adult, Antidepressive Agents, Major Depressive Disorder, Double-Blind Method, Female, Humans, Ketamine, Male, Middle Aged, Young Adult, Suicidal Ideation, Nasal Sprays
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.